Nasal dexmedetomidine and heart muscle injury in people having a coronary stent procedure
Tests nasal dexmedetomidine against saline in people having coronary artery procedures.
Plain-language title generated from the registry record
Registry title: Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary Interventions
Key facts
- Where
- Hangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 45-85 with coronary artery disease who are planned for an elective stent procedure (PCI). It tests a nasal spray of dexmedetomidine against saline to see if it reduces heart muscle injury after the procedure.
- Age
- 45 to 85 years (inclusive)
- Sex
- All sexes can join
- Disease stage
- Coronary artery disease with objective evidence of ischemia or silent ischemia, planned for elective PCI. ASA physical status II-III.
- Earlier treatment
- Must not have used drugs that may interfere with the study drug within 1 week before surgery, such as clonidine or other α2-adrenergic receptor agonists or antagonists, or tricyclic antidepressants.
Main reasons for not taking part
- Allergy or contraindication to dexmedetomidine, such as resting heart rate under 50 beats/min, sick sinus syndrome, or second-degree or higher heart block without a pacemaker
- Severe heart failure (LVEF under 40% or NYHA class III-IV), cardiogenic shock or unstable blood circulation
- Uncontrolled high blood pressure (over 180/110 mmHg) or low blood pressure (systolic under 90 mmHg)
- BMI over 30 kg/m², or known or suspected sleep apnea
- Pregnant or breastfeeding women
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 85 years old?
Source: NCT07847580, who can take part
Where in China
- The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaContact: Min Yan, DoctorNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT07847580
- Record updated
- 29 September 2026
- Original description
The goal of this clinical trial is to determine the effect of pre-operative dexmedetomidine on periprocedural myocardial injury in patients having percutaneous coronary intervention (PCI). The specific research hypothesis is that intranasal administration of 100 μg dexmedetomidine (DEX) reduces the incidence of periprocedural myocardial injury within 48 hours after PCI, as compared with normal saline.Read full original descriptionShow less
Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary Interventions: A Prospective, Multi-Center Randomized Trial
The goal of this clinical trial is to determine the effect of pre-operative dexmedetomidine on periprocedural myocardial injury in patients having percutaneous coronary intervention (PCI). The specific research hypothesis is that intranasal administration of 100 μg dexmedetomidine (DEX) reduces the incidence of periprocedural myocardial injury within 48 hours after PCI, as compared with normal saline.
Participants will be randomly assigned in a 1:1 ratio to two groups: the dexmedetomidine group and the placebo group.
Inclusion: Aged 45-85 years(inclusive); Able to confirm understanding of risks, benefits, and treatment alternatives of receiving intranasal dexmedetomidine, and he/she or his/her legally authorized representative provides written informed consent prior to any study-related procedure; Diagnosed with coronary artery disease with objective evidence of ischemia or silent ischemia, meeting the indications for elective PCI; Designated American Society of Anesthesiologists (ASA) physical status II-Ⅲ (ranging from mild systemic disease to severe underlying conditions; patients with marked limitation in ordinary physical activity, yet still capable of light daily activities).
Exclusion: Use of drugs that may interfere with the study medication within 1 week before surgery, including α2-adrenergic receptor agonists (e.g., clonidine) or antagonists, and tricyclic antidepressants; Allergy or contraindication to dexmedetomidine, including severe sinus bradycardia (resting heart rate < 50 beats/min), sick sinus syndrome, second-degree or higher atrioventricular block without pacemaker implantation; Uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg) or hypotension (systolic blood pressure < 90 mmHg); Language, visual, or hearing impairment that may affect questionnaire assessment; Patients with severe cardiac insufficiency (left ventricular ejection fraction < 40% or New York Heart Association functional class Ⅲ-IV), cardiogenic shock, or hemodynamic instability; Hepatic or renal insufficiency (Alanine Aminotransferase/Aspartate Aminotransferase/Creatinine > 3 times the upper limit of normal); BMI > 30 kg/m²; Known or suspected sleep apnea; Nasal anatomical abnormalities interfering with nasal spray administration; Pregnant or lactating women; Participation in another clinical trial that may conflict with this trial.